The 20 most recent market catalysts affecting $AMLX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57
Guggenheim analyst Seamus Fernandez has maintained a 'Buy' rating on Amylyx Pharmaceuticals and raised the price target from $55 to $57. This action signals continued bullish senti…
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, Amylyx Pharmaceuticals Prices Upsized $500M Public Offering Of 14,090,000 Common Shares At $35.50 Per Share
This headline signifies a significant capital raise for Amylyx Pharmaceuticals, providing crucial funding for its operations. While the offering itself can cause short-term dilutio…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 65
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42
Mizuho analyst Graig Suvannavejh maintained an 'Outperform' rating on Amylyx Pharmaceuticals (AMLX) and significantly raised the price target from $30 to $42. This upgrade signals …
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 75
Amylyx Pharmaceuticals shares are trading higher after Baird and Guggenheim raised their respective price targets on the stock,
This headline indicates a strong positive catalyst for Amylyx Pharmaceuticals (AMLX). Upgrades from prominent investment banks like Baird and Guggenheim signal increased confidence…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55
Guggenheim analyst Seamus Fernandez maintained a 'Buy' rating on Amylyx Pharmaceuticals and raised the price target from $40 to $55. This action signals increased confidence from a…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 65
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52
Baird analyst Joel Beatty maintained an 'Outperform' rating on Amylyx Pharmaceuticals (AMLX) and raised the price target from $28 to $52. This significant increase in the price tar…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 75
Amylyx Pharmaceuticals Announces $350M Common Stock Offering
This common stock offering by Amylyx Pharmaceuticals (AMLX) is a significant corporate catalyst. The primary impact will be on AMLX shares, which are likely to face downward pressu…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55
HC Wainwright & Co. analyst Andrew S. Fein has maintained a 'Buy' rating on Amylyx Pharmaceuticals (AMLX) and raised the price target from $34 to $55. This substantial increase in …
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 95
Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level
Amylyx Pharmaceuticals reported successful Phase 3 trial results for avexitide, its investigational drug for post-bariatric hypoglycemia (PBH). The drug demonstrated a significant …
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 95
Amylyx Pharmaceuticals shares are trading higher after the company announced topline results from LUCIDITY Phase 3 trial met its primary endpoint.
The positive topline results from the LUCIDITY Phase 3 trial for AMX0035 in Progressive Supranuclear Palsy (PSP) are a major catalyst for Amylyx Pharmaceuticals. Meeting the primar…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 95
Amylyx Pharmaceuticals Says LUCIDITY Phase 3 Trial Met Its Primary Endpoint, Demonstrating 55% Reduction in Level 2 and Level 3 Hypoglycemic Events Vs. Placebo
Amylyx Pharmaceuticals reported that its LUCIDITY Phase 3 trial for avexitide successfully met its primary endpoint, demonstrating a 55% reduction in Level 2 and Level 3 hypoglycem…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 75
Amylyx Pharmaceuticals shares are trading higher after the company announced it will reveal its topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026.
The announcement of an upcoming Phase 3 topline results reveal is a significant corporate catalyst for Amylyx Pharmaceuticals. Positive results for Avexitide in Post-Bariatric Hypo…
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 75
Amylyx Pharmaceuticals To Announce Phase 3 LUCIDITY Trial Topline Results For Avexitide In Post-Bariatric Hypoglycemia On August 18 At 8:00 a.m. ET
Amylyx Pharmaceuticals is announcing the upcoming release of topline results for its Phase 3 LUCIDITY trial of Avexitide. This is a critical juncture for the company, as the succes…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30
This filing discloses that Mizuho has maintained its 'Outperform' rating on Amylyx Pharmaceuticals and raised its price target from $24 to $30. This is a positive signal for AMLX i…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Amylyx Pharma shares are trading higher despite reporting weak Q2 results. The market may be looking ahead to a pivotal Phase 3 LUCIDITY trial data readout, with strong cash reserves and clear regulatory strategy reducing risk and fueling optimism.
This headline indicates a classic 'buy the rumor, sell the news' scenario, or in this case, 'buy the future news' despite current weakness. The market is clearly prioritizing the p…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028
Amylyx Pharma (AMLX) reported a wider-than-expected Q2 loss, missing analyst estimates. This is a negative short-term indicator for the company's financial performance. However, th…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26
Citigroup analyst Geoff Meacham maintained a 'Buy' rating on Amylyx Pharmaceuticals and raised the price target from $20 to $26. This action signals increased confidence from a pro…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $24
Mizuho analyst Graig Suvannavejh has maintained an 'Outperform' rating on Amylyx Pharmaceuticals (AMLX) and raised the price target from $21 to $24. This action signals continued c…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.